2335 GMT - Sonic Healthcare lacks national scale in the U.S. despite investing A$2.3 billion in M&A there, and Barrenjoey says the path to growing its footprint is unclear. So, Barrenjoey explores a possible sale of the U.S. business and concludes it would be highly attractive to Sonic's bigger rivals. Assuming a sales price of 11-14x FY 2026 Ebitda, with proceeds used on a share buyback, Sonic's proforma EPS could change by -1% to +6% that year, Barrenjoey says. Sonic's return on invested capital could improve to 6.8%, from 6.5%. "While not necessarily financially compelling, the broader benefits of such a transaction include a decrease in maintenance capex into the U.S. region, and the ability to deploy future capital into higher returning regions such as Germany (via bolt-ons)," analyst Saul Hadassin says. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
March 26, 2025 18:35 ET (22:35 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.